{
AstraZeneca PLC

Companies

}
Symbol AZN
Name AstraZeneca PLC
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Pharmaceuticals
Market NASDAQ Global Select
Country United Kingdom
State
City Cambridge
Zipcode CB2 0AA
Website http://www.astrazeneca.com
Track all markets on TradingView
China's ensartinib gains FDA approval for lung cancer treatment
Xcovery Holdings' ensartinib, branded as Ensacove, has received FDA approval as a first-line treatment for ALK-positive non-small cell lung cancer, marking a significant milestone as the first innovative targeted lung cancer drug from a Chinese company to enter the U.S. market. While it shows a 44% reduction in progression or death compared to Pfizer's Xalkori, it faces stiff competition from established ALK inhibitors like Roche's Alecensa, which has demonstrated superior efficacy in previous studies. Despite its potential, Ensacove's market entry comes amid a landscape dominated by major pharmaceutical players.
Fierce Pharma
United States Dollar Chinese Yuan Swiss Franc Japanese Yen AstraZeneca PLC Hoffmann-La Roche AG Pfizer Inc. Novartis AG CHN USA JPN Show more
Healthcare, Market Report
16:20 19.12.2024
AstraZeneca Expands US Operations Amid Challenges in China
AstraZeneca is enhancing its global operations with a $3.5 billion investment in the U.S. through 2026, creating over 1,000 high-skilled jobs, while navigating challenges in China following leadership changes. Strong demand for cancer and rare-disease treatments has led to improved financial performance, prompting a raised sales outlook. The company’s strategic refresh includes new board appointments to bolster governance and digital capabilities, reflecting confidence in its growth trajectory.
IG
AstraZeneca PLC Sonova R Arm Holdings plc USA CHN GBR Birgit Conix René Haas Iskra Reic Leon Wang Show more
Healthcare, Market Report
09:55 18.12.2024
global bisoprolol fumarate market poised for significant growth through 2032
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
openPR.com
United States Dollar Merck & Co., Inc. Amgen Inc. Alkem Laboratories Limited Mylan Pharmaceuticals Inc. Aurobindo Pharma Limited Teva Pharmaceutical Industries Ltd Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Limited CIPLA LTD Sandoz Group AG Pfizer Inc. Bayer AG Hikma Pharmaceuticals PLC AstraZeneca PLC Novartis AG Torrent Pharmaceuticals Limited Sanofi IND ROU BEL HUN DNK POL IDN SGP ARE BRA ZAF FRA THA MEX CZE GBR CHL AUT SAU SWE NOR NLD USA ARG MYS SVK CAN NZL LKA JPN DEU RUS KOR CHN VNM Nidhi Bhavsar Show more
Regulatory & Legal, Market Report
13:09 16.12.2024
breakthrough therapy designation market projected to reach 287.5 billion by 2029
The Breakthrough Therapies Market is projected to grow from USD 150.6 billion in 2024 to USD 287.5 billion by 2029, achieving a CAGR of 13.80%. The report analyzes risks, benefits, and competitive strategies related to breakthrough therapy designation across various therapeutic areas, including oncology and rare diseases, while profiling key market players and trends.
GlobeNewswire News Room
United States Dollar Bristol-Myers Squibb Co Merck & Co., Inc. AstraZeneca PLC F. Hoffmann-La Roche Ltd. Novartis AG Show more
Healthcare, Market Report
17:02 13.12.2024
global growth trends in the crispr and cas gene market to 2033
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
GlobeNewswire News Room
United States Dollar Bayer AG Bio-Rad Laboratories, Inc. Pluristem Therapeutics Inc. Genscript Biotech Corporation AstraZeneca PLC Qiagen N.V. Hologic, Inc. Cellectis S.A. Takara Bio Inc. Vertex Pharmaceuticals Inc Thermo Fisher Scientific Inc. Sigma-Aldrich Co. LLC Regeneron Pharmaceuticals Inc Editas Medicine Inc IND GBR ESP CAN AUS ITA IDN JPN BRA DEU FRA RUS KOR CHN USA Show more
Technology & Innovation, Market Report
15:27 13.12.2024
topical corticosteroids market poised for growth with emerging opportunities and trends
The global Topical Corticosteroids market, valued at approximately US$ 4.12 billion in 2022, is projected to grow at a CAGR of 4.36% through 2030. The report provides an extensive analysis of market dynamics, competitive landscape, and consumption trends, highlighting key players like GlaxoSmithKline and Merck & Co. It also explores opportunities for growth driven by increasing demand across various industries, while addressing challenges such as supply chain disruptions and changing consumer preferences.
openPR.com
Merck & Co., Inc. AstraZeneca PLC Almirall S.A. A Bristol-Myers Squibb Company Glaxosmithkline plc Leo Pharma AB Bausch Health Companies Inc. IND GBR CAN SAU JPN BRA DEU FRA MEX CHN USA Viju Shah Alice Mutum Show more
Healthcare, Market Report
11:04 13.12.2024
Ionis Pharmaceuticals Reports Narrower Loss Amid Revenue Decline in Q3 2024
Ionis Pharmaceuticals reported a narrower loss of 95 cents per share for Q3 2024, beating estimates, while total revenues reached $134 million, surpassing expectations but declining 7% year over year. Commercial revenues fell to $76 million, missing estimates, with Spinraza royalties down 15%. Adjusted operating costs decreased 4.2% year over year, although expenses rose due to increased SG&A costs for new product launches.
Yahoo Finance
United States Dollar BIOGEN Ionis Pharmaceuticals, Inc. AstraZeneca PLC GBR USA Show more
Healthcare, Market Report
17:31 06.12.2024
AstraZeneca and Daiichi Sankyo Advance Cancer Drug Amid Industry Developments
AstraZeneca and Daiichi Sankyo announced new study results for their cancer drug datopotamab deruxtecan, showing a median survival of 15.6 months in patients with EGFR-mutated non-small cell lung cancer. Agenus plans to cut annual spending by 60% to focus on a late-stage cancer immunotherapy, while Amgen is investing $1 billion to expand its manufacturing in North Carolina. The U.S. Patent and Trademark Office has withdrawn a proposed rule aimed at reducing patent thickets, and Bluebird bio is executing a reverse stock split to comply with Nasdaq rules. Merus received FDA accelerated approval for zenocutuzumab, its first approved product.
BioPharma Dive
bluebird bio, Inc. AstraZeneca PLC Daiichi Sankyo Co Ltd Amgen Inc. Merus N.V. Delilah Alvarado Ned Pagliarulo Jonathan Gardner Ben Fidler Show more
Healthcare, News Article
01:00 06.12.2024
AstraZeneca Appoints Iskra Reic as New International Business Head
AstraZeneca Plc has appointed Iskra Reic as executive vice-president of its international business, succeeding Leon Wang, who is currently under investigation by Chinese authorities. This change comes shortly after the company confirmed Wang's detention, where he also served as president of Astra's China division.
Bloomberg.com
AstraZeneca PLC GBR Leon Wang Iskra Reic
Regulatory & Legal, News Article
16:07 04.12.2024
Republican Control Promises Major Shifts in Healthcare and Pharma Policies
The incoming Trump administration and a Republican-controlled Congress are expected to significantly impact healthcare policy, particularly regarding the Affordable Care Act, Medicaid, and Medicare drug price negotiations. Analysts predict a net negative effect on healthcare companies' credit ratings due to potential increases in uninsured populations and regulatory changes, while decreased scrutiny on mergers and acquisitions may benefit the pharmaceutical sector. Additionally, rising tariffs on medical supplies could further strain the industry amid ongoing inflationary pressures.
Fierce Healthcare
United States Dollar AstraZeneca PLC Sanofi Merck & Co., Inc. Pfizer Inc. GSK plc IND USA CHN Mike Johnson Robert F. Kennedy Jr. Donald Trump Lina Khan Show more
Healthcare, Market Report
23:30 03.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.